Home›Trial›NCT07186595
NCT07186595Phase 4Completed

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.

Conditions
Mid Face Volume Deficit
Interventions / Drugs
JUVÉDERM VOLUX XCJUVÉDERM VOLUMA XCJUVÉDERM VOLBELLA XCJUVÉDERM VOLLURE XCSKINVIVE by JUVÉDERMJUVÉDERM ULTRA XCJUVÉDERM ULTRA PLUS XC
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C52/100
Study Details
Enrollment75 participants
Primary Completion2026-07-08
Lead SponsorAbbVie
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2026-07-08
Enrolled: 75 participants
Sponsor Catalyst Profile

AbbVie Inc (ABBV) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ABBV Full Pipeline →All Companies →
Other Trials from AbbVie Inc
NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's …(PHASE3)NCT05407636Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD(PHASE3)NCT06858813A Study to Assess Adverse Events and Change in Disease Activity of Intravenously…(PHASE1)NCT03568318A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in …(PHASE3)NCT04780516Study to Assess Change in Disease Symptoms in Adult Participants With Moderate t…
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence